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Abstract
T-cell based vaccines have been considered as attractive candidates for prevention of hep-
atitis C virus (HCV) infections. In this study we compared the magnitude and phenotypic
characteristics of CD8+ T-cells induced by three commonly used viral vectors, Adenovirus-5
(Ad5), Vaccinia virus (VV) and Modified Vaccinia Ankara (MVA) expressing the HCV NS3/
4A protein. C57/BL6 mice were primed with DNA expressing NS3/4A and boosted with
each of the viral vectors in individual groups of mice. We then tracked the vaccine-induced
CD8+ T-cell responses using pentamer binding and cytokine production analysis. Overall,
our data indicate that the memory cells induced by Ad5 were inferior to those induced by
VV or MVA. We found that Ad5 boosting resulted in rapid expansion and significantly higher
frequencies of NS3-specific T-cells compared to VV and MVA boosting. However, the func-
tional profiles, assessed through analysis of the memory cell marker CD127 and the anti-
apoptotic molecule Bcl-2 in the blood, spleen, and liver; and measurements of interferon-
gamma, tumor necrosis factor-alpha, and interleukin-2 production indicated significantly
lower frequencies of long-lived memory T-cells following Ad5 boosting compared to VV and
MVA. This same set of analyses suggested that the memory cells induced following boost-
ing with MVA were superior to those induced by both Ad5 and VV. This superiority of the
MVA-induced CD8+ T-cells was confirmed following surrogate challenge of mice with a
recombinant mouse herpes virus expressing the HCV NS3 protein. Higher levels of NS3-
specific CD8+ T-cells displaying the functional markers CD69, Ki67 and Granzyme B were
found in the spleens of mice boosted with MVA compared to VV and Ad5, both alone and in
combination. These data suggest that MVA may be a more successful viral vector for induc-
tion of effective CD8+ T-cell responses against hepatitis C virus.
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Introduction
Hepatitis C virus (HCV) infection is a global health threat. About 180 million people worldwide
are chronically infected, with about 500,000 HCV-related deaths each year [1, 2]. Current drug
therapies can clear the majority of HCV infections [3], but treatment success can be limited by
numerous factors including access to care, cost of therapy, patient adherence, relative efficacy of
different regimens, side effects, viral genotype and host factors. It is also unclear if individuals
are protected from reinfection following drug treatment. Drug treatment of acute phase HCV
infections has been shown to result in functional CD4+ and CD8+ T-cell responses [4], how-
ever, such responses have not been shown in patients successfully treated during the chronic
phase [5]. Therefore, a prophylactic vaccine is still needed to prevent HCV infections across the
globe.
A large body of evidence has shown that cellular immunity plays a major role in controlling
acute HCV infections [6–12]. Several studies have reported that broad, polyclonal CD4+ and
CD8+ T-cell responses are present in patients with self-resolved infections [8–14] and chim-
panzee studies have shown that T-cells play a pivotal role during secondary exposure after
spontaneous clearance and in protection from persistent infection [15–17]. For these reasons
T-cell-based vaccines for HCV are highly attractive and represent an important and rapidly
developing class of vaccines as prophylaxis for prevention and control of several chronic dis-
eases such as HCV, HIV, tuberculosis and Malaria.
Successful T-cell immunity requires long-term immunological memory that can be rapidly
reactivated to substantially reduce the viral loads and prevent the risk of developing chronic
infection upon re-exposure. The HCV T-cell based vaccine studies reported thus far confirm
that a vaccine-induced T-cell response can contribute significantly to the control of virus repli-
cation but persistent infections have frequently been seen in immunized chimpanzees following
virus challenge [18] with a possibility of immune escape from the vaccine-induced immune
responses. We have previously shown that an ineffective T-cell vaccine against HCV can create
greater pressure for viral mutation and therefore immune escape, which may lead to persistence
despite initial control of the virus [19]. We subsequently showed that memory T-cell responses
leading to clearance of HCV are phenotypically different from those that result in persistence of
the virus [20] suggesting that the magnitude of the response is less important than the func-
tional quality of the induced T-cells.
The HCV-NS3 protein has been shown to be highly immunogenic, inducing a diverse rep-
ertoire of cell-mediated immune responses, and the importance of T-cells directed to this anti-
gen for controlling viral replication have been widely reported [6, 21, 22]. In these studies we
wished to determine if different viral vectors induce qualitatively different T-cell responses
against the HCV NS3 antigen which may be helpful in predicting the optimal immunization
method for an HCV vaccine. Studies on HCV vaccines are largely hampered by the lack of a
small animal model. Chimpanzees remain the only animal model for this virus where the out-
come of infection in the presence of memory immune response can be established [23], how-
ever, the availability of these animals for biomedical research has become limited. Therefore,
we sought to use a mouse model to evaluate phenotypic differences between T-cells induced
by different viral vectors following priming with DNA. The DNA prime/viral vector boost
approach has been used in many experimental HCV T-cell vaccines in the past, most of which
have included the HCV NS3 protein as a target for immune responses with varying outcomes
[24]. We primed mice with plasmid DNA containing the full-length HCV-NS3/4A transgene
followed by boosting with either Adenovirus 5 (Ad5), Vaccinia virus (VV) or Modified Vac-
cinia Ankara (MVA)-HCV-NS3/4A vectors. The correlates of protection after T-cell based
vaccination are complicated and differ with each pathogenic antigen. However, certain
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canonical biomarkers and functional qualities expressed by antigen-experienced T-cells in the
memory stage may present clues to the qualitative differences among various vaccine plat-
forms [25, 26]. Therefore, we assessed the vaccine-induced HCV-NS3-specific CD8+ T-cells
by pentamer binding assays, characterized memory phenotypic markers of the pentamer posi-
tive CD8+ T-cells and assayed for IFN-γ, TNF-alpha and IL-2 cytokine production profiles.
We also assessed the phenotypes of the recall response to NS3-specific T-cells following surro-
gate challenge with mouse herpes virus expressing the HCV NS3 protein.
Materials and methods
Viral vectors and MHV-68-NS3 construction
Plasmid DNA containing the entire sequence of the HCV NS3/4A genes (Genotype 1a, strain
H77) was produced as previously described [19]. Modified Vaccinia Ankara-NS3 (MVA-NS3),
[27], Vaccinia virus (WR)-NS3 (VV-NS3) [28] and Adenovirus 5-NS3 (Ad5-NS3) [19] con-
structs were generated as previously described. MHV-68-NS3 for challenge was characterized
and reconstituted as previously described [27].
Mouse studies
All experiments were approved by the Intramural Animal Care and Use Committee of the
Center for Biologics Evaluation and Research, Food and Drug Administration and carried out
in strict adherence to the approved protocol, including efforts to minimize suffering of study
animals. Mice were housed and maintained according to NIH Animal Research Advisory
Committee guidelines. For intramuscular inoculations animals were anesthetized using 3%
isoflurane inhalation. For tissue isolation animals were euthanized with carbon dioxide inhala-
tion in a euthanasia chamber. Female C57BL/6J (B6) mice were obtained from Jackson Labo-
ratories (Bar Harbor, ME) at 6–8 weeks old and housed in the US-FDA animal research
facility.
Primary response for identification of T-cell epitopes
B6 mice were immunized with 2x106 pfu/mouse of VV-NS3 via intraperitoneal injections or
109 viral particles (vp)/mouse of Ad5-NS3 delivered intramuscularly. Control mice were inoc-
ulated with Null-VV or Null-Ad5 (empty Ad5 or VV vectors).
Prime-boost
Plasmid DNA expressing the HCV NS3/4A protein under the control of a CMV promoter was
administered at 100 μg/mouse delivered via intramuscular injections to the hind quadriceps of
B6 mice. At day 85 post prime, groups of mice were boosted via intra-peritoneal injections
with 2x106 pfu/mouse of VV-NS3 (VV), 108 infectious units (IU) of MVA-NS3 (MVA) or via
intramuscular injections with 109 vp of Ad5-NS3 (Ad5).
Direct challenge
B6 memory mice (85 days post boost) were challenged with 105 pfu/mouse of MHV-68-NS3
live virus via intraperitoneal injections. Mice were sacrificed at day 2, 6, 9, 13 and 16 post chal-
lenge to harvest spleens and blood for proliferation studies. Virus titers were assessed on D2,
D4, D6, D9, D12 and D14 by plaque assay as previously described [29].
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In vivo assays and cell isolation
Lymphocytes from the spleens, livers, and blood were isolated to assess kinetics of antigen-spe-
cific CD8+ T-cells. Spleens were homogenized into single cell suspension and red blood cells
were lysed by using ACK lysing buffer (Life Technologies, Grand Island, NY) according to the
manufacturer’s protocol. Splenocytes were then washed twice with RPMI supplemented with
5% FBS, penicillin-streptomycin and L-glutamine (R-5). Finally, the splenocytes were resus-
pended in RPMI supplemented with 10% FBS (R-10). Livers were perfused with 20ml PBS
during harvest and collected in RPMI + 5% FBS. The livers were homogenized to single cell
suspension, washed and resuspended in 44% Percoll (R10 + Percoll) and then underlaid with
67% Percoll (1X PBS + Percoll). The Percoll gradient was centrifuged at 2000 rpm (400 x g) for
20 minutes at room temperature (RT) with no brake. After centrifugation, the interface con-
taining the lymphocytes was collected and washed twice with R5 and resuspended in an appro-
priate volume of the R10 medium to attain 1–2 million cells/mL. Blood lymphocytes were
isolated by underlaying with 2 mL of Histopaque (Sigma, St Louis, MO) and centrifuged at
2000 rpm at RT for 20 minutes. The interface was collected and washed twice with R5 and
then resuspended in an appropriate volume of R10 medium.
Antibodies, pentamer staining and flow cytometry
MHC class I H2-Db pentamer with the sequence GAVQNETVL (GAVQ) was purchased from
ProImmune (Oxford, UK) and stained according to the manufacturer’s recommendation. Sple-
nocytes were stimulated with NS3 peptide pools (18-mers overlapping by 11 amino-acids, NIH
AIDS Reagent Program) or with individual peptides representing the various epitopes (Mimo-
topes, Australia). Cells were stimulated in 96 well round bottom plates with 1.5 million cells/
well and 0.5μg of peptide supplemented with 2 μL Brefeldin and 2 μL Monensin per mL of R10
and incubated for 5 hours at 37˚C before performing intracellular cytokine staining with anti-
bodies. Surface staining of fluorescence-conjugated antibodies was performed according to the
manufacturer’s protocol or titration. For intracellular staining, cells were permeabilized with
cytoperm/cytofix (Becton Dickinson, Franklin Lakes, NJ) by following the manufacturer’s pro-
tocol before staining with fluorescence-conjugated antibodies. Cellular events were acquired
using a FACS Canto II (BD Biosciences, San Jose, CA) multi-parameter flow cytometer. The fol-
lowing antibodies were used: Bcl-2, Ki67, CD8, CD19, CD44, Ly6C, CD62L, CD27, IFN-γ,
TNF-alpha, IL-2, CD107a/b, CD4 (BD Biosciences, San Jose, CA), CD127 (E-Bioscience, San
Diego, CA), CD43 (1B11), CD3, CD69 (Biolegend, San Diego, CA), fixable live-dead near IR
(Life Technologies, Grand Island, NY).
Data and statistical analyses
Flow data were analyzed with Flowjo software (Treestar, Ashford, OR) and graphical representa-
tions generated by Graphpad Prism V5 (Graphpad, San Diego, CA). Statistical analyses were
performed by using a one-way analysis of variance (ANOVA) in Graphpad software to compare
means for T-cell responses. When a statistically significant difference between the means was
determined using one-way ANOVA a Bonferroni post hoc analysis was used to assess differences
between the means of each immunized group. A p value of< 0.05 was considered significant.
Results
Identification of novel H2-Db CD8+ T-cell epitopes
There exists a commercially available pentamer for the HCV-NS3 protein which includes the
GAVQNEVTL sequence located at aa1629-1637 of the HCV polyprotein. In order to obtain a
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broader range of peptides for testing responses to HCV-NS3 in the B6 mice we performed an
analysis to identify new epitopes using a GAVQNEVTL peptide as the positive control. Pep-
tides representing GT1a-H77 spanning the entire HCV NS3 sequence were synthesized as
18mers overlapping by 8 amino acids (Mimotopes, Clayton, Australia). Splenocytes from
Ad5-NS3 and VV-NS3 immunized mice were isolated and stimulated with pools of 9–10 NS3
peptides per reaction and screened for IFN-γ cytokine production by flow cytometry. After the
initial screening, peptides from positive pools were individually used for repeated stimulation
of IFN-γ production to identify the specific epitope sequence. From this analysis four 18mer
peptides were identified that yielded specific IFN-γ responses in CD8+ T-cells in addition to
the GAVQNETVL sequence: #7080- WTVYHGAGTRTIASPKGP (aa1079-1096), #7119 –
PGSVTVSHPNIEEVALST (aa1352-1369), #7121 –ALSTTGEIPFYGKAIPLE (aa1366-1383),
and #7122 –IPFYGKAIPLEVIKGGRH (aa1373-1390) (data not shown). A library of 9mer and
15mer peptides was then synthesized for re-screening and finer mapping of the specific epi-
tope sequences. Four 9mer peptides located within these 18mers were identified as novel CD8
+ T-cell epitopes GAGTRTIAS (#7080–10), VSHPNIEEV (#7119–37), ALSTTGEIP (#7121–
15), and YGKAIPLEV (#7122–25) (Fig 1). These peptides or the original 18mers were used for
stimulation of splenocytes as indicated below.
Ad5-NS3 boosting induces a higher magnitude of CD8+ T-cell
responses
To characterize the immune response elicited post vaccination, we first primed groups of B6 mice
with 100 μg/mouse of plasmid DNA expressing the HCV-NS3/4A delivered intramuscularly via
Fig 1. Identification of HCV-1a H77-NS3 CD8+ epitopes in the H2-b mouse system. Representative flow plots of IFN-γ positive
CD8+ T-cells from the spleens of mice immunized with Ad-5-NS3/4A. Cells from immunized mice were isolated and stimulated with
0.1 μg/well of each peptide for 5 hours. The sequences GAGTRTIAS (aa1084-1092), ALSTTGEIP (aa1366-1374), YGKAIPLEV
(aa1376-1384) and VSHPNIEEV (1357–1365) were 9 mers identified as CD8+ T-cell epitopes within the HCV NS3. Amino acid
numbering is according to the H77 GT1a polyprotein sequence. Blue numbers on the plots are percentages gated on live CD8+ T-
cells (right panels) and CD8+ T-cells positive for CD44 and IFN-γ. Red numbers on the plots represent mean fluorescence intensity
for CD8+/CD44+/IFN-γ+ cells. Negative control represents mock stimulated cells. These experiments were repeated at least 5 times.
https://doi.org/10.1371/journal.pone.0181578.g001
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the hind quadriceps muscles. At D10 post prime, HCV-NS3 MHC class I H2Db pentamer+
(GAVQ) CD8+ T-cells were detectable in the blood of immunized mice at between 0.05–2.1% of
total CD8+ T-cells (mean of 0.8% for n = 39) (Fig 2A). These values corresponded to 1 to 38-fold
over the frequencies observed in naïve mice tested in the same assay (Fig 2B). The mean frequen-
cies declined to about 0.5% by D75 post prime (n = 3); this corresponded to a 2 to 4-fold increase
over naïve mice tested in the same assay (Fig 2A and 2B). We also analyzed tissues of immunized
mice at D75 to assess the numbers of NS3-specific CD8+ T-cells maintained in both the lymphoid
and non-lymphoid compartments and found the highest number of cells were maintained in the
spleen (~100,000 cells) and bone marrow (BM ~90,000 cells), with ~103 to 104 cells in the liver,
inguinal lymph nodes, mesenteric lymph nodes and blood (Fig 2C).
Fig 2. Magnitude of CD8+ T-cell responses post immunization. (A) HCV-NS3 pentamer positive (Pent+) CD8+ T-cells present in the blood of mice after
priming with 100μg of plasmid DNA containing the full length HCV-NS3/4A gene insert at D10 (n = 39) and D75 (n = 3) post DNA immunization. Horizontal
bars represent the mean frequency in each group (B) Representative flow plots of CD44+/Pent+ cells isolated from the blood of DNA immunized mice at D10
and D75 Black numbers on the plots are percentages positive for CD44 and pentamer after gating on CD8+ and CD3+ cells. (C) Numbers of Pent+ CD8+ T-
cells accumulated in both lymphoid and non-lymphoid tissues of immunized mice at D75 post DNA-NS3/4A prime. PBMCs were enumerated based on per
million cells. n = 3 mice per group.
https://doi.org/10.1371/journal.pone.0181578.g002
Qualitatively different T-cells induced by different viral vectors
PLOS ONE | https://doi.org/10.1371/journal.pone.0181578 July 21, 2017 6 / 20
Mice were then boosted with 109 vp of Ad5-NS3/4A (Ad5), 2x106 pfu of VV-NS3/4A (VV)
or 108 IU of MVA-NS3/4A (MVA) at D85 post prime and the kinetics of secondary antigen-
specific CD8+ T-cell responses in the blood and tissues were assessed using MHC Class I pen-
tamer (H2Db-GAVQ) binding assays. Comparisons between the peak responses for the three
vaccine vectors indicated that Ad5 was significantly more immunogenic than MVA or VV,
both of which showed a similar magnitude of responses (S1 Fig). Tremendous expansion of
the pentamer+ CD8+ T-cells was observed in the blood, spleen and liver of mice boosted with
Ad5 (Fig 3A–3C). At D7 post boost (D92 post immunization), the magnitude of pentamer
+ CD8+ T-cells in the blood after Ad5 administration was ~4-fold higher than boosting with
MVA (p<0.0001) and ~8-fold higher than boosting with VV (p<0.0001) (Fig 3A). Similar dif-
ferences in the magnitude of responses were also found in the spleens and livers of immunized
mice (Fig 3B and 3C). The peak response to the Ad5 boost was at D14 in the blood, spleen and
liver (Fig 3A–3C) while peak responses for VV were observed at D21 post boost in all tissues
analyzed. Interestingly, boosting with MVA showed a peak response in the blood at D21 but
delayed responses in the spleen and liver (D28 post boost) compared to Ad5 and VV (Fig 3A–
3C).
T-cell expansion at D7 post boost in all tissues analyzed was higher in Ad5 immunized
mice compared to MVA or VV immunized mice (Fig 4A). These differences were found to
be statistically significant in the spleen, inguinal lymph nodes, and PBMC. Contraction of
NS3-specific CD8+ T-cells was observed by D42 post boost (D127 post immunization) in the
tissues amongst all vaccination regimens (Figs 3 and 4B). However, Ad5 boosted mice showed
a sustained level of pentamer+/CD8+ T-cells in blood and tissue compartments compared to
VV and MVA (Figs 3 and 4B).
In order to assess the breadth of CD8+ T-cell responses we stimulated splenocytes from
immunized mice at D7 post boost with NS3 peptides representing different CD8+ T-cell epi-
topes and stained for IFN-γ. Our results showed that boosting with Ad5, MVA and VV gener-
ated antigen-specific CD8+ T-cells that are targeted towards the dominant GAVQ epitope and
sub-dominant #7080, #7122, and #7119 epitopes in a hierarchical manner (Fig 4C) with the
strongest responses being maintained in Ad5 immunized mice. These data show that all three
vaccines are able to elicit a broad CD8+ T-cell response towards various epitopes of the
Fig 3. Kinetics of antigen-specific secondary effector CD8+ T-cell expansion of immunized mice after boosting. Mice were primed with DNA and
boosted with Ad5-NS3/4A (Ad5) (109 vp), VV-NS3/4A (VV) (2 x 106 pfu) and MVA-NS3/4A (MVA) (108 IU). (A) Blood (n = 7). (B) Spleen (n = 3–4 mice per
group) and (C) Liver (n = 3–4 mice per group). Error bars represent standard error of the mean. Asterisks represent significance analyses following post hoc
Bonferroni testing between Ad5 and VV or Ad5 and MVA immunized mice. * = p value <0.05; ** = p value<0.01, *** = p value <0.0001. Where different p
values were obtained for VV and MVA compared to Ad5 the lower value is represented.
https://doi.org/10.1371/journal.pone.0181578.g003
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HCV-NS3 protein but that Ad5 is significantly more immunogenic than MVA and VV in
boosting antigen-specific responses post DNA priming in mice.
Ad5 boosting induces qualitatively different memory CD8+ T-cells
To determine the phenotypes of the NS3-specific CD8+ T-cells, we analyzed several pheno-
typic markers that are routinely used to differentiate effector and memory CD8+ T-cells. We
examined the quality of the vaccine-induced memory CD8+ T-cells by studying the expression
kinetics of CD127, a hallmark feature of long-lived memory T-cells, Bcl-2 (anti-apoptotic mol-
ecule), CD62L (lymphoid trafficking marker), CD44 –a cell adhesion receptor, which is essen-
tial for cell trafficking and highly expressed on activated and memory T- and B-cells, CD27 –a
costimulatory molecule for T lymphocytes, CXCR3 –a chemokine receptor which is highly
expressed in activated T, B and NK cells for chemotaxis, and Ly6C –a GPI-linked surface anti-
gen found on most cells and which is also a memory marker for CD8+ T-cells.
The kinetics of most markers when analyzed as a frequency within total CD8+ cells were
similar to those seen for pentamer positive cells with higher frequencies seen in the Ad5
Fig 4. Numbers of pentamer+ CD8+ T-cells present in tissue compartments. (A) D7 post boost, n = 3–4 mice per group. (B) D42 post boost, n = 3–4
mice per group. (C) Breadth of antigen-specific CD8+ T-cell response shown as IFN-γ production upon stimulation with peptides representing four different
CD8 T-cell epitopes of the HCV-NS3 antigen at D7 post boost. n = 3–4 mice per group Error bars represent standard error of the mean. ns = no significance
between the means determined by one-way ANOVA. Asterisks represent significance analyses following post hoc Bonferroni testing between Ad5 and VV
or Ad5 and MVA immunized mice. * = p value <0.05; ** = p value<0.01, *** = p value <0.0001.
https://doi.org/10.1371/journal.pone.0181578.g004
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boosted group (data not shown). However, for some markers this was not the case which
prompted us to analyze the frequency of cells within the pentamer positive group alone. We
observed similar frequencies of pentamer positive cells expressing CD27, CD44, CXCR3,
CD62L and Ly6C in the blood and tissues of all boosted mice (data not shown). However, the
expression kinetics of CD127 and Bcl-2 in the blood, spleens and livers of pentamer positive
cells from Ad5 boosted mice were significantly lower compared to the VV and MVA boosted
mice (Fig 5). Although we observed statistically significant differences between Ad5 and VV
immunized mice at several time points, for clarity, significant differences in Fig 5 are only
shown for Ad5 compared to MVA immunized mice. At Day 0, data from all immunized mice
showed high expression (>90% of cells positive) for both CD127 and Bcl-2 on the small num-
bers of pentamer positive cells detected (data not shown). At D7 post boost all groups of immu-
nized mice displayed down-regulated expression of CD127 and Bcl-2 on pentamer+ cells in the
blood, spleen and liver (Fig 5A–5F). These two markers were observed to re-express at D14 post
boost but with a consistently lower level of expression in the Ad5 boosted mice than for the
other 2 groups. In the blood, we observed that Ad5 boosted mice re-expressed significantly
lower levels of pentamer+ CD127 throughout the post challenge period (Fig 5A) compared to
MVA and VV boosted mice. Statistically significant differences in the expression of CD127 in
the spleen at D42 post boost (Fig 5B) and liver at D21, (Fig 5C) were also observed. Similarly,
statistically significant differences in the expression of Bcl-2 were noted in the blood, spleen and
liver throughout the post challenge period (Fig 5D–5F). Notably, these differences were still
detected at the memory time point in the spleen and liver (D42 post boost). These data suggest
that although Ad5 boosting after DNA priming generated significantly more HCV-specific
CD8+ T-cells, this population in the Ad5 boosted mice displayed differential expression of
memory cell markers with a lower proportion of optimal memory phenotypes of CD8+ T-cells
induced.
Ad5 induced NS3-Specific CD8+ T-cells are less multifunctional than
those induced by VV and MVA
Primed CD8+ T-cells produce several cytokines in the infected microenvironment that are
required for the continued activation, expansion and cytolytic potential of T-cells [26]. In
these studies, we examined the IL-2, IFN-γ and TNF-α cytokine production capacity of CD8
+ T-cells after brief restimulation with antigen. Splenocytes from immunized mice at D7 and
D28 post boost were isolated and stimulated with GAVQ peptide for five hours to induce pro-
duction of intracellular cytokines. The frequencies of IFN-γ+/TNF-α+ and IFN-γ+/IL-2+ co-
producing CD8+ T-cells were consistently higher in the Ad5 boosted mice at D7 post boost
(Fig 6A). However, at D28 the MVA boosted mice appear to maintain the frequency of double
cytokine producing cells while the levels in both Ad5 and VV boosted mice decreased to less
than 50% of those seen at D7 (Fig 6B). In order to more closely compare the functional abilities
of cells from the three vaccinated groups, we compared the frequencies of IFN-γ-producing
CD8+ T-cells with the mean fluorescence intensity (MFI) of IFN-γ on a per cell basis after
stimulation with the dominant GAVQ (Fig 6C) and sub-dominant #7080 and #7122 peptides
(S2 Fig). We found that the Ad5 boosted group consistently generated a higher frequency of
IFN-γ producing cells when compared to VV or MVA in response to stimulation by the three
peptides throughout the course of vaccination from D7 to D42 (Fig 6C and S2 Fig, left panels).
Interestingly, an inverse relationship was observed when compared with the MFI for IFN-γ.
Although VV and MVA boosted mice have a lower frequency of IFN-γ producing CD8+ T-
cells, the IFN-γ production capacity on a per cell basis was greater within these groups than for
Ad5 boosted mice (Figs 6C and S2, right panels). Thus, although the Ad5 boost generated a
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Fig 5. Phenotypes of GAVQ Pent+ CD8+ T-cells in the tissues of immunized mice after boosting with Ad5-, VV- or
MVA-NS3/4A vectors. Kinetics of CD127 expression in (A) blood; (B) spleen, and (C) liver. Kinetics of Bcl-2 expression in (D)
blood, (E) spleen, and (F) liver, Blood n = 7 mice per group, spleen and liver n = 3–4 mice per group. Error bars represent
standard error of the mean. For clarity asterisks represent significance analyses following post hoc Bonferroni testing between
Ad5 and MVA immunized mice. * = p value <0.05; ** = p value<0.01, *** = p value <0.0001.
https://doi.org/10.1371/journal.pone.0181578.g005
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high frequency of IFN-γ producing CD8+ T-cells, the fitness of these cells to produce copious
amount of IFN-γ is not as high as that for cells boosted with VV or MVA.
Fig 6. Functional characteristics of cytokine production capacities of HCV-NS3 antigen-specific CD8+ T-cells
post boost with Ad5-, VV- or MVA-NS3/4A vectors. Freshly isolated splenocytes were stimulated with 0.1 ug/well of
GAVQ peptide per 1.5 million cells and cultured in 10% FBS plus RPMI medium at 37˚C for 5h. (A) Representative flow
plots of intracellular staining of IFN-γ, TNF-α, and IL-2 in stimulated and unstimulated effector CD8+ T-cells (D7 post
boost) and (B) memory precursor CD8+ T-cells (D28 post boost). Left panels show IFN-γ+/TNF-α+ co-producers and right
panels show IFN-γ+/IL-2+ co-producers. Numbers in plots are representative percentages of cytokine producers. n = 3–4
mice per group. (C) Frequency (left) and mean fluorescence intensity (MFI, right) of IFN-γ producing CD8+ T-cells
stimulated by GAVQpeptide. Error bars represent standard error of the mean. Asterisks represent significance analyses
following post hoc Bonferroni testing between Ad5 and VV or Ad5 and MVA immunized mice. * = p value <0.05; ** = p
value<0.01, *** = p value <0.0001.
https://doi.org/10.1371/journal.pone.0181578.g006
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We further compared the frequencies of CD8+ T-cells producing multiple cytokines simul-
taneously when stimulated with GAVQ, #7080 and #7122 peptides. Fig 7 shows the percentage
of triple, double and single cytokine producers amongst all IFN-γ positive cells at D7 (Fig 7A)
and D42 (Fig 7B) post boost. At D7, there was a trend for Ad5 boosted mice to produce fewer
triple and double cytokine producing cells (Fig 7A, left panels) although these differences were
not found to be statistically significant. At D42 (memory) Ad5 boosted mice also produced
lower frequencies of triple (IFN-γ+ TNF-α+ IL-2+) and double (IFN-γ+ TNF-α+ or IFN-γ
+ IL-2+) cytokine producers specific for all three peptides and the differences were found to be
statistically significant for triple producers specific for the immunodominant peptide GAVQ
compared to both VV and MVA boosted mice (Fig 7B). These results demonstrate that
although Ad5 boost generated a high frequency of IFN-γ producing cells, these cells are less
multifunctional than those induced by VV and, in particular, by MVA.
Higher proliferation potential and cytolytic activity of MVA-induced
antigen-specific CD8+ T-cells during direct challenge and recall of
memory CD8+ T-cells
Thus far, our studies showed that VV and MVA boosted mice generated HCV-NS3-specific
memory CD8+ T-cells that appear to be more long-lived and polyfunctional in producing
IFN-γ, TNF-α and IL-2 compared to Ad5 boosted mice. To determine if these differences
influence the proliferation potential during recall of the secondary memory CD8+ T-cell
response, we performed a surrogate challenge of immunized mice at D85 post boost (memory)
with 105 pfu of murine γ-herpes virus-68 (MHV-68) expressing the HCV NS3 (MHV-68-NS3)
[27]. To compare responses between secondary memory and primary immunization expan-
sion of CD8+ T-cells, we also challenged naïve mice with the same dose of MHV-68-NS3. We
harvested the blood and spleens of mice at D2, D6, D9, D13 and D16 post challenge for com-
parative studies using the NS3-specific pentamer (GAVQ). We also assessed virus titers in the
spleens of mice at D2, D4, D6, D9, D12 and D14.
MHV-68-NS3 titers peaked in naïve mice at D4 post challenge (~3x103 pfu/spleen) (data
not shown). However, we were unable to quantify virus in the spleens of any immunized mice
challenged with MHV-68-NS3. Previous data showed that immunization with MVA-OVA
resulted in significant reductions in intrasplenic virus titers following challenge with MHV-
68-OVA [29], to levels below the limit of detection. We concluded that the immune responses
induced by all three vaccine regimens effectively controlled the MHV-68-NS3 replication.
Therefore, for these studies the MHV-68-NS3 challenge served as a means to examine the
characteristics of the recall response in immunized mice.
At D2 post challenge, pentamer+ CD8+ T-cells were detected with minimal expansion in
both the blood and spleens (Fig 8A and 8B). However, expansion of the NS3 antigen-specific
CD8+ T-cells increased to a similar degree at D6 in all immunized mice, to a peak of ~30% in
the blood (Fig 8A) and ~20% in the spleen (Fig 8B) by D9 post challenge. As expected, in all
analyses we observed minimal expansion of NS3-specific CD8+ T-cells during primary infec-
tion with MHV-68-NS3 (MHV 1˚) in all tissues analyzed (Fig 8). We next compared the early
activation marker CD69, the proliferation marker Ki67, and Granzyme B (GmB) (representa-
tive of cytolytic activities of activated CD8 T-cells) in the blood and spleens of challenged
mice.
We found that activation of CD69 peaked at D9 post challenge in the blood for all three vac-
cination regimens (Fig 8C, left panel) while in the spleen the peak activation was at D6 for the
MVA vaccinated group and at D9 for the VV and Ad5 group (Fig 8C, right panel). Prolifera-
tion of the expanded CD8+ T-cells, as assessed by Ki67, showed a peak response at D9 for the
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Fig 7. Frequencies of polyfunctional CD8+ T-cells post boost with Ad5-, VV- or MVA-NS3/4A vectors. Cells
were stimulated with GAVQ, #7080 and #7122 at (A) D7 and (B) D42 post boost. Values are presented as single,
double and triple cytokine-producing cells as a % of total IFN-γ positive cells. Asterisks represent significance analyses
following post hoc Bonferroni testing between Ad5 and VV or Ad5 and MVA immunized mice. * = p value <0.05; ** = p
value<0.01, *** = p value <0.0001. ns = non-significant, n = 3–4 mice per group. Error bars represent standard error of
the mean.
https://doi.org/10.1371/journal.pone.0181578.g007
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Fig 8. Recall expansion of HCV-NS3 antigen-specific CD8+ T-cells upon challenge with MHV-68-NS3 in
immunized mice. Expansion of tertiary effector CD8+ T-cells of immunized memory mice (3˚) in comparison with
primary effector expansion in naïve mice (MHV 1˚) challenged with MHV-68-NS3 in (A) blood and (B) spleen. (C)
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all boosted groups (Fig 8D, left panel) while in the spleen all groups showed peak proliferation
at D6 post challenge (Fig 8D, right panel). In contrast, GmB production peaked at D6 post
challenge in the blood and spleens of all immunized mice (Fig 8E). Although the kinetics of
NS3-specific T-cell expansion following challenge with MHV-68-NS3 was similar amongst all
immunized groups of mice, we observed consistently higher levels of CD8+/pentamer+ cells
that were also positive for CD69+, Ki67+ and GmB+ in the spleens of MVA immunized mice.
We have previously shown that CD8+ T-cells that are both proliferating and activated
are associated with clearance in immune primed chimpanzees following infection with
HCV [20]. Therefore, we analyzed the frequencies of cells expressing combinations of the
CD69, Ki67, and GmB markers (CD69+/Ki67+, CD69+/GmB+,and Ki67+/GmB+ cells) in
the blood and spleens of immunized mice following challenge. We found that mice immu-
nized with MVA-NS3 had higher frequencies of cells expressing CD69 in combination with
Ki67 or GmB at the peak time points during the post challenge period in the blood and
spleens (Fig 9). These data further indicate that the secondary memory cells recalled after
challenge with virus expressing the HCV NS3 protein are qualitatively different in the Ad5
immunized mice and suggest that NS3-specific memory T-cells induced by MVA have
higher proliferative and cytolytic capacities.
Discussion
HCV persists in the majority of infected individuals but it is cleared in a small proportion of
cases, which results in memory responses that lead to early and rapid control of the virus upon
subsequent reinfection [30, 31]. Despite this development of natural immunity to the virus fol-
lowing clearance, the development of vaccines to prevent HCV infection has proved challeng-
ing. Phase I clinical trials have shown that immune responses to the virus can be induced with
recombinant proteins or viral vectors [32, 33].
In this study, we compared three viral vectors (Ad5, VV and MVA) commonly used for the
induction of T-cell responses against transgenes and have shown significant differences in the
memory CD8+ T-cells induced against the HCV NS3 protein which could prove pivotal in the
control and clearance of HCV following infection. Our data show that boosting with Ad5 fol-
lowing DNA priming leads to rapid expansion of NS3-specific CD8+ T-cells in B6 mice result-
ing in significantly higher frequencies than those obtained following VV or MVA boosting.
These differences were maintained across different tissues (blood, spleen and liver) against
multiple HCV-NS3 epitopes and throughout the follow up period post boost (Fig 2). However,
when the T-cell responses were analyzed for specific memory cell markers, we found that Ad5
induced lower frequencies of CD8+ T-cells expressing the memory cell marker CD127 and
fewer CD8+ T-cells expressing the anti-apoptotic molecule Bcl-2 in the blood, spleen, and liver
compared to cells induced by VV and MVA. This difference was observed throughout the post
boost follow-up period, and the differences were found to be significant (Fig 3). The T-cell phe-
notypes in the liver compartment could be particularly relevant for the control of HCV as this is
the primary site of viral replication in the body. The quality of memory T-cells has been linked
with the expression of CD127 [34] and Bcl-2; [35] thus despite high levels of NS3-specific T-
cells induced by Ad5, a lower proportion of these cells appear to be associated with memory
function. This conclusion was further confirmed when cytokine production and polyfunction-
ality were assessed in stimulated T-cells. There appeared to be a rapid expansion of cytokine
Expression of the early activation marker CD69 on pentamer+/CD8+ T-cells upon challenge with MHV-68-NS3 in
the blood and spleen of immunized mice. (D) proliferation marker KI67 (E) cytolytic activity marker Granzyme B.
Error bars represent standard error of the mean (n = 3–5 mice).
https://doi.org/10.1371/journal.pone.0181578.g008
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producing cells following Ad5 boosting but this response also contracted rapidly compared to a
steady maintenance of HCV-specific T-cells in mice boosted with VV and MVA. More impor-
tantly, the per cell production of IFN-γ was inferior in the Ad5 boosted group compared to the
VV and MVA boosted groups as the numbers of polyfunctional CD8+ T-cells were significantly
lower in the Ad5 boosted group at later time points as evidenced by the frequencies of triple
and double cytokine-producing cells.
Fig 9. Recall expansion of HCV-NS3 antigen-specific CD8+ T-cells expressing combinations of markers
for proliferation (CD69), activation (Ki67) or cytolytic activity (GmB) in the blood and spleens upon
challenge with MHV-68-NS3 in immunized mice. Error bars represent standard error of the mean, n = 3–5 mice
per group.
https://doi.org/10.1371/journal.pone.0181578.g009
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Overall, our data suggested that the memory cells induced by Ad5 were inferior to those
induced by VV or MVA. In addition our data suggested that the memory cells induced follow-
ing boosting with MVA were superior to those induced by both Ad5 and VV boost. The num-
bers of cells expressing CD127 and Bcl-2 were generally higher for MVA boosted mice in the
blood, spleen, and liver, the per cell IFN-γ production was highest for CD8+ cells from mice
boosted with MVA, and also the proportion of polyfunctional CD8+ NS3-specific cells was
consistently higher in the MVA boosted mice. Following tertiary exposure to the HCV NS3
antigen, through challenge with the MHV-68-NS3 recombinant virus, we observed expansion
of HCV-specific cells in response to infection in all immunized groups but MVA boosted mice
showed consistently higher levels of cells expressing CD69, Ki67 or Granzyme B, markers that
are commonly identified with functional T-cell activation in response to antigens. In addition,
the MVA-immunized mice displayed higher levels of cells that were both activated and prolif-
erating. We have previously shown that ineffective T-cell responses following immune priming
in chimpanzees are associated with qualitative differences in memory T-cells and, specifically
that proliferating, activated memory CD8+ T-cells are associated with clearance [20].
As expected all three vectors in this study elicited HCV-specific memory T-cells that were
recalled upon exposure to virus expressing the NS3 antigen, indicating that all three vectors
induced memory T-cell responses. However, the control of HCV replication and the progres-
sion to chronic infection appears to be a very subtle process that is not solely dependent on the
presence or absence of immune responses. T-cell based chimpanzee vaccine studies have all
induced HCV-specific immune responses, regardless of the immunogen used, and in all cases
viral replication is controlled rapidly following challenge with HCV [18]. However, despite
this early control, the outcome from challenge has still resulted in persistence of the virus in a
large percentage of challenged animals [18]. Thus it appears that T-cell responses induced by
vaccination have the ability to control viral replication immediately following challenge but
cannot maintain the control; leading to long-term persistence. The maintenance of specific
memory T-cells could be the critical difference between clearance of virus and persistence. The
previous chimpanzee vaccine studies used all three vectors examined in our studies either
alone or in combination with DNA priming; persistence and clearance occurred in immunized
animals regardless of the vector used [18]. We previously assessed if the type of recombinant
viral vector used to induce T-cells in these experimental vaccines impacted the outcome of
infection after challenge but found the rate of persistence or clearance could not be associated
with any particular vector [18]. The numbers of animals per group, different challenge doses
of HCV and the inclusion of different antigens in the vaccines makes direct comparisons diffi-
cult. The majority of studies did not examine T-cell phenotypes or memory markers following
immunization or challenge of animals, therefore conclusions on the role of T-cell memory in
the success or failure of any one vaccine is challenging.
The differences we observed for NS3-specific CD8+ T-cell kinetics and memory pheno-
types may partly be explained by the kinetics and magnitude of transgene expression by each
of the viral vectors we studied. Levels and longevity of antigen can influence cytokine expres-
sion and stimulatory signals that lead to the differentiation and survival of memory T-cells.
We found that the Ad5 vector used in our studies expresses higher levels of transgene than the
VV and MVA vectors (data not shown) which may account for the rapid expansion of specific
T-cells post boost with the Ad5 vector. However, other studies have shown that the levels of
antigen expression by viral vectors post boost have a minimal effect on T-cell differentiation as
the duration of expression is brief in all cases [36]. Conversely, the Ad5 vector used in our
studies was replication incompetent while the VV vector was a replicating virus which would
result in cell-to-cell spread and new viral infections suggesting that although the initial levels
of antigen expressed by the Ad5 vector may be higher the expression of antigen by VV would
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continue for longer periods of time. Non-replicating MVA lacks many of the immune evasion
factors VV uses to interfere with key innate immune responses of the host which may explain
for the particular immunomodulatory capacity of MVA-based vaccines (for review see [37]).
Native viral antigens expressed as part of the vectors during protein expression could equally
account for the impact on T-cell differentiation and development, such as CD4+ responses to
viral vector antigens. As has been previously reported memory CD8+ T-cell responses induced
by different viral vectors exhibit different functional qualities [36]. We show here that differ-
ences are maintained during subsequent exposure of immunized mice to the HCV NS3 anti-
gen following challenge with a surrogate virus and that the differences are associated with
memory T-cell phenotypes shown to be important for HCV clearance. Overall, our data indi-
cate that the magnitude of specific cells induced during immunization is not necessarily an
indicator of quality and suggest that MVA or VV represent a better alternative for induction of
memory T-cells against the HCV NS3 protein compared to Ad5; which could have a consider-
able impact on the development of vaccines against this agent.
Supporting information
S1 Fig. Magnitude of CD8+ T-cell responses post immunization. Representative flow plots
of HCV-NS3 GAVQNEVTL (GAVQ) Pent+ CD8+ T-cell responses in the blood of mice after
heterologous prime-boost immunization. Black numbers represent the percentage of CD8
+/Pentamer+ cells.
(TIF)
S2 Fig. IFN-γ production in by peptide stimulated CD8+ T-cells. Functional characteristics
of cytokine production capacities of HCV-NS3 antigen-specific CD8+ T-cells post boost with
Ad5-, VV- or MVA-NS3/4A vectors. Frequencies (left) and mean fluorescence intensity (MFI,
right) of IFN-γ producing CD8+ T-cells stimulated by #7080 and #7122 peptides. #7122 data
for D14 not shown. Error bars represent standard error of the mean. Asterisks represent signif-
icance analyses following post hoc Bonferroni testing between Ad5 and VV or Ad5 and MVA
immunized mice.  = p value<0.05;  = p value<0.01,  = p value <0.0001. ns = no signifi-
cant differences between the means assessed by one way ANOVA.
(TIF)
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